{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:26:30Z","timestamp":1783146390154,"version":"3.54.6"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is related to the production of reactive oxygen species (ROS) and oxidative stress, so antioxidant treatment can prevent its further development. Ultrasmall copper-based nanoparticles (CuNPs) have shown multiple enzyme-like activities for scavenging oxygen species, providing a new strategy for the treatment of inflammatory diseases. Resveratrol (Res), a natural polyphenol compound, has attracted much attention due to its ability to inhibit oxidative stress. We therefore aimed to first combine these two agents for the treatment of NAFLD. However, due to the poor water solubility and stability of Res, which is easily metabolized in the intestine, the development of a stable and effective carrier became the key to achieving a synergistic effect. Liver-targeted nanocarriers loaded with bioactive compounds may provide a more effective approach for the treatment of NAFLD. Therefore, we developed a novel ultrasonic nanobubble carrying nucleic acid aptamers with liver targeting properties, which has the advantages of a small molecular weight, no immunogenicity, a low cost of synthesis, and high stability through chemical modification. Res and the ultrasmall CuNPs were specifically delivered to liver tissue to maximize therapeutic efficiency. This study found that the combination of these two components can effectively treat inflammation in NAFLD and suggested that liver-targeted NAFLD-specific aptamer-mediated targeted ultrasound nanobubbles that can simultaneously deliver Res and CuNPs may be a safe and effective new platform for NAFLD and other liver diseases.<\/jats:p>","DOI":"10.3389\/fphys.2022.950141","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T18:56:42Z","timestamp":1662749802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Xinmin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"184241","DOI":"10.1155\/2015\/184241","article-title":"Antiviral activity of resveratrol against human and animal viruses","volume":"2015","author":"Abba","year":"2015","journal-title":"Adv. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41698-017-0038-6","article-title":"The therapeutic potential of resveratrol: A review of clinical trials","volume":"1","author":"Berman","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jnutbio.2016.10.012","article-title":"Antioxidant properties of tea blunt ROS-dependent lipogenesis: Beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model","volume":"40","author":"Braud","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijpharm.2018.06.064","article-title":"Mediterranean essential oils as precious matrix components and active ingredients of lipid nanoparticles","volume":"548","author":"Carbone","year":"2018","journal-title":"Int. J. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejpb.2016.07.007","article-title":"Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy","volume":"107","author":"Chen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/164_2020_352","article-title":"Nonalcoholic fatty liver disease","volume":"270","author":"Ding","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/pharmaceutics12100964","article-title":"Microbubbles and nanobubbles with ultrasound for systemic gene delivery","volume":"12","author":"Endo-Takahashi","year":"2020","journal-title":"Pharmaceutics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/15734064113096660053","article-title":"Chemistry, stability and bioavailability of resveratrol","volume":"10","author":"Francioso","year":"2014","journal-title":"Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8543763","DOI":"10.1155\/2018\/8543763","article-title":"Molecular pathogenesis of nonalcoholic steatohepatitis- (NASH-) related hepatocellular carcinoma","volume":"2018","author":"Kutlu","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/s41467-020-16544-7","article-title":"Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-012-0004-0","article-title":"Nonalcoholic fatty liver disease: Current issues and novel treatment approaches","volume":"73","author":"Lomonaco","year":"2013","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.biopha.2017.08.070","article-title":"Resveratrol and diabetes: A critical review of clinical studies","volume":"95","author":"\u00d6zt\u00fcrk","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1021\/acs.analchem.0c04866","article-title":"CD36 as a molecular target of functional DNA aptamer NAFLD01 selected against NAFLD cells","volume":"93","author":"Pu","year":"2021","journal-title":"Anal. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1039\/c7fo01300k","article-title":"A comprehensive review of the health perspectives of resveratrol","volume":"8","author":"Rauf","year":"2017","journal-title":"Food Funct."},{"key":"B17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1055\/s-2007-985075","article-title":"Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents","volume":"27","author":"Schwimmer","year":"2007","journal-title":"Semin. Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2019.04.023","article-title":"FA-NBs-IR780: Novel multifunctional nanobubbles as molecule-targeted ultrasound contrast agents for accurate diagnosis and photothermal therapy of cancer","volume":"455","author":"Shen","year":"2019","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2147\/IJN.S238587","article-title":"Ultrasound mediated destruction of LMW-HA-loaded and folate-conjugated nanobubble for TAM targeting and reeducation","volume":"15","author":"Sun","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/cas.12867","article-title":"Tumor growth suppression by the combination of nanobubbles and ultrasound","volume":"107","author":"Suzuki","year":"2016","journal-title":"Cancer Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","article-title":"The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"307","author":"Teng","year":"2019","journal-title":"J. Control. Release"},{"key":"B22","doi-asserted-by":"publisher","first-page":"181457","DOI":"10.1098\/rsos.181457","article-title":"Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy","volume":"5","author":"Wan","year":"2018","journal-title":"R. Soc. open Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/IJN.S230879","article-title":"G250 antigen-targeting drug-loaded nanobubbles combined with ultrasound targeted nanobubble destruction: A potential novel treatment for renal cell carcinoma","volume":"15","author":"Yu","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.2147\/IJN.S176287","article-title":"CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors","volume":"13","author":"Zhu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejpb.2015.04.002","article-title":"Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature","volume":"93","author":"Zupan\u010di\u010d","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.950141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T18:56:43Z","timestamp":1662749803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.950141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":26,"alternative-id":["10.3389\/fphys.2022.950141"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.950141","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"article-number":"950141"}}